Shares of Kura Oncology Inc. (NASDAQ:KURA) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus price target of $20.00 for the company and are predicting that the company will post ($0.41) EPS for the current quarter, according to Zacks. Zacks has also given Kura Oncology an industry rank of 109 out of 265 based on the ratings given to related companies.
Several equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, September 20th. Leerink Swann reiterated an “outperform” rating and set a $15.00 price target on shares of Kura Oncology in a report on Thursday. Finally, Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $16.00 price target on shares of Kura Oncology in a report on Sunday, August 14th.
An institutional investor recently bought a new position in Kura Oncology stock. Alethea Capital Management LLC bought a new position in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned 0.34% of Kura Oncology as of its most recent filing with the SEC. 43.63% of the stock is owned by institutional investors.
Shares of Kura Oncology (NASDAQ:KURA) opened at 5.5699 on Friday. Kura Oncology has a 12-month low of $2.50 and a 12-month high of $25.00. The firm’s market capitalization is $104.40 million. The firm’s 50-day moving average is $6.16 and its 200-day moving average is $4.20.
Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. Equities research analysts forecast that Kura Oncology will post ($1.58) EPS for the current fiscal year.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.